Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales

Citations Over TimeTop 10% of 2021 papers

Abstract

Imipenem/relebactam, colistin and ceftazidime/avibactam were the most active antimicrobials against all CPEs. Imipenem/relebactam is a valuable addition to the antimicrobial arsenal used in the fight against CPE, particularly against KPC-producing isolates, which in all cases were susceptible to this combination.

Related Papers

• → Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop(2015)133 cited
• → Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa(2012)115 cited
• → In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens(2016)24 cited
• → In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against Pseudomonas aeruginosa(2022)15 cited
• → Potentiation of ceftazidime by avibactam against β-lactam-resistantPseudomonas aeruginosain anin vitroinfection model(2016)19 cited